Palafer® CF
Natural health product licensed in Canada
- Licence holder
- Bausch & Lomb Inc.
- NPN or DIN-HM
- 01923455
- Status
- Active licence
- Licence date
- 27 March 2009
- Revision date
- 7 February 2024
- Form
- Capsule
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Rouge FD & C #3, Stéarate de magnésium, FD & C Jaune no. 6, Talc, Eau purifiée, Lactose Monohydrate, Jaune D & C No. 10, Dioxyde de titane, Lauryl sulfate de sodium, Sucrose, Gélatine, Povidone, FD & C bleu #1, FD&C Red No. 2, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | Not specified |
| Enfants | minimum: 12 years | 1 Capsule | Not specified |
Uses authorised in Canada
Text supplied in English because no French text is available.
Iron therapy. For the prevention and treatment of iron and folic acid deficiencies. For the prevention and treatment of iron deficiency and iron deficiency anemia. Mineral supplement. Vitamin supplement. Helps reduce the risk of neural tube defects when taken daily prior to becoming pregnant and during early pregnancy. A factor in the maintenance of good health. Helps the body to metabolize proteins and fat. Helps in the development and maintenance of bones, cartilage, teeth and gums. Helps to form red blood cells and helps in their proper function. Helps in connective tissue formation and wound healing. An antioxidant for the maintenance of good health. Helps to prevent Vitamin C deficiency. Helps to prevent folate deficiency. Additional information for health care practitioners: Prophylactic administration of Palafer CF should be discontinued at term. Iron therapy alone should be administered after parturition. Iron poisoning is rare in adults but serious acute poisoning in children can result from ingestion of doses in excess of 1 g. Doses of 1 g should be considered as toxic in children and therapy instituted as soon as possible. Serum iron levels above 500 mcg/100 mL can be presumptive evidence of poisoning; severe poisoning is usually associated with levels well above 1000 mcg/100mL. Symptoms may occur within about 30 minutes or may be delayed several hours. They are largely those of gastrointestinal irritation and necrosis with vomiting, diarrhea, tarry stools, hematemesis, fast and weak pulse, lethargy, low blood pressure, coma and signs of peripheral circulatory collapse. There may be a transient period of apparent recovery after 4 to 6 hours followed by a second crisis characterized by cyanosis, pulmonary edema, circulatory collapse, convulsion, and coma may then occur followed by death in 12 to 48 hours. Treatment; Milk should be given immediately and vomiting induced. Eggs and milk should then be fed (to form Iron-protein complexes) until it is possible to perform gastric lavage with 1% sodium bicarbonate solution (to convert the iron to a less soluble form). Gastric lavage should not be performed after the first hour of iron ingestion because of the danger of perforation due to gastric necrosis. If an iron-chelating agent such as deferoxamine mesylate is available, it should be utilized. BAL (dimercaprol) should not be used because it may form a toxic complex. Measures to combat shock, dehydration, blood loss and respiratory failure may be necessary.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 01923455
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging